Clinical trials: Atypical Nevi
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS)
The Cancer of the Pancreas Screening-5 CAPS5)Study
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
- Conditions
- Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier
- Trial name
- CAPS5 (NCT02000089)
- Testing
- Secretin, MRI, Tumor marker gene test with CA19-9
- Where
- 9 sites in United States
- Volunteers
- 9,000 people
- Sponsor
- Johns Hopkins University
Uveal Melanoma, Cutaneous Melanoma
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
This research will have a significant impact on the overall management of those cancer patients and their family members who are at risk for hereditary cancer due to germline inactivation of BAP1.
- Conditions
- Uveal Melanoma, Cutaneous Melanoma, BAP1 Gene Mutation, Renal Cell Carcinoma
- Trial name
- NCT04792463
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Mohamed Abdel-Rahman
Melanoma (Skin), Basal Cell Carcinoma
Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage
The purpose of this clinical study is to evaluate if the DermaSense prototype EIS scanner can provide medical decision support which can complement dermoscopy-based identification of the disease at time of biopsy decision.
- Conditions
- Melanoma (Skin), Basal Cell Carcinoma, Squamous Cell Carcinoma, Dysplastic Nevus Syndrome
- Trial name
- DermaSense (NCT04688749)
- Testing
- Electrical Impedence Spectroscopy DermaSense
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Aristotle University Of Thessaloniki
Nevus, Dysplasia; Epithelial
Skin Fluorescent Imaging (SFI) System in Patients With Nevi
The Sponsor has developed the Skin Fluorescent Imaging (SFI) system, an in vivo imaging modality, for the purpose of providing physicians with insight into the biological changes occurring during tissue remodeling in a nevus.
- Trial name
- NCT04368247
- Testing
- Skin Fluorescent Imaging
- Where
- 4 sites in United States
- Volunteers
- 300 people
- Sponsor
- Orlucent, Inc
Melanoma, Pigmented Skin Lesion
Artificial Intelligence-assisted Evaluation of Pigmented Skin Lesions
Malignant melanoma (MM) is a deadly cancer, claiming globally about 160000 new cases per year and 48000 deaths at a 1:28 lifetime incidence (2016).
- Conditions
- Melanoma, Pigmented Skin Lesion, Dysplastic Nevi
- Trial name
- NNCD (NCT03362138)
- Testing
- dermoscopy
- Where
- Israel
- Volunteers
- 80 people
- Sponsor
- Assuta Hospital Systems
Clinically Atypical Pigmented Skin Lesion
MelaFind Evaluations for Patients With Multiple Nevi
We have added objectives 4-6 to our updated study: Study Objective 1: To determine whether the distribution of MelaFind scores is different for different patients with multiple nevi, and whether such distributions can be utilized…
- Trial name
- NCT01700101
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- MELA Sciences, Inc.
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
Sulforaphane for the Prevention of Melanoma in Patients With Multiple Atypical Nevi and a Prior History of Melanoma
This phase II trial tests how well sulforaphane works in preventing melanoma in patients with multiple atypical moles (nevi) and a prior history of melanoma.
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8
- Trial name
- NCT07040280
- Testing
- Biopsy Procedure, Biospecimen Collection, Sulforaphane
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous Melanoma
The clinical objective of this clinical trial is to examine the clinical activity in terms of tumor response and time to treatment failure of the immunotherapeutic product GSK2132231A when given to patients with unresectable and…
- Trial name
- NCT00896480
- Testing
- Immunotherapeutic GSK2132231A
- Where
- 8 sites in Belgium, France
- Volunteers
- 24 people
- Sponsor
- GlaxoSmithKline
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Dermatitis, Nevus
Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles
This study will evaluate whether digital photography is a reliable tool for diagnosing hand rashes, psoriasis and unusual moles.
- Conditions
- Dermatitis, Nevus, Psoriasis
- Trial name
- NCT00005781
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- National Cancer Institute (NCI)
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer, Pancreas Cancer
Pancreatic Cancer Early Detection Program
Early detection testing is recommended for individuals at elevated risk for the development of Pancreatic Cancer. This Protocol will define sufficiently elevated risk as either equal to or greater than five times the general…
- Conditions
- Pancreatic Cancer, Pancreas Cancer, Pancreatic Adenocarcinoma, Familial Pancreatic Cancer
- Trial name
- PCEDP (NCT02206360)
- Testing
- Endoscopic Ultrasound, Magnetic Resonance Imaging (MRI)
- Where
- United States
- Volunteers
- 181 people
- Sponsor
- White Plains Hospital
Melanoma
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
A novel infrared imaging tool to aid in the clinical detection of atypical pigmented lesions and melanoma is developed. Goals include evaluation of the utility of high-resolution infrared scanning of cutaneous lesions in the…
- Trial name
- NCT01118832
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Basal Cell Carcinoma, Squamous Cell Carcinoma
Photochemical Tissue Bonding
The broad aim of this study is to evaluate the efficacy of photochemical tissue bonding (PTB) for the closure of skin excisions.
- Conditions
- Basal Cell Carcinoma, Squamous Cell Carcinoma, Atypical Nevus
- Trial name
- PTB (NCT00586040)
- Testing
- tissue bonding, sutures
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer
A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups
PanFAM-1 is a clinical study for early detection of pancreatic cancer in high-risk groups. The goals of the study are to assess the performance and diagnostic accuracy of the IMMray™ PanCan-d test compared to standard-of-care…
- Conditions
- Pancreatic Ductal Adenocarcinoma, Familial Pancreatic Cancer, FAMMM - Familial Atypical Mole Malignant Melanoma Syndrome
- Trial name
- NCT03693378
- Where
- 21 sites in United States, Canada and 3 more
- Volunteers
- 1,349 people, healthy volunteers welcome
- Sponsor
- Immunovia, Inc.
Pancreatic Neoplasms, Peutz-Jegher's Syndrome
Pancreatic Cancer Screening of High-Risk Individuals in Arkansas
100 subjects who have a family history of pancreatic cancer (PC), or known genetic syndromes associated with increased risk of pancreatic cancer, will be followed for five years.
- Conditions
- Pancreatic Neoplasms, Peutz-Jegher's Syndrome, BRCA1 Gene Mutation, BRCA2 Gene Mutation
- Trial name
- NCT02309632
- Testing
- Pancreatic Cancer Screening Pathway 1, Pancreatic Cancer Screening Pathway 2
- Where
- United States
- Sponsor
- University of Arkansas
Malignant Melanoma, Merkel Cell Carcinoma
Optical Biopsy of Human Skin in Conjunction With Laser Treatment
This study is to compare the ability of optical biopsy. Research can use light enters the skin, collected, analyzed by the computer, and a picture created for the pathologist to conventional histologic examination compare with…
- Conditions
- Malignant Melanoma, Merkel Cell Carcinoma, Basal Cell Carcinoma, Squamous Cell Carcinoma
- Trial name
- NCT00540566
- Testing
- Optical Biopsy imaging
- Where
- United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Skin Lesion, Melanoma (Skin)
Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging)
The goal of the SFI is to provide non-invasive information about tissue remodeling occurring during melanocytic transition and atypia development in the skin
- Conditions
- Skin Lesion, Melanoma (Skin), Mole
- Trial name
- NCT03535077
- Testing
- Diagnostic Test
- Where
- 6 sites in United States
- Volunteers
- 186 people
- Sponsor
- Orlucent, Inc
Dysplastic Nevus, Health Status Unknown
Internet-based Intervention for Skin Self-Examination in Participants With Increased Risk for Melanoma
This trial studies an internet-based intervention for skin self-examination (SSE) in participants at increased risk for melanoma. Early detection of suspicious growths on the skin can be done by performing regular SSE checks.
- Conditions
- Dysplastic Nevus, Health Status Unknown, Melanoma, No Evidence of Disease
- Trial name
- NCT03725449
- Testing
- Best Practice, mySmartCheck, Survey Administration
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Segmental Dysplastic Nevi
Genetic Identification (ID) of Segmental Dysplastic Nevi
The investigators' goal is to identify the mutation in the gene that is responsible for the development of segmental dysplastic nevi. To identify the gene the investigators may use a candidate gene approach (i.e.
- Trial name
- NCT00955578
- Testing
- Punch Biopsy
- Where
- Canada
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nova Scotia Health Authority